David Henry Mack - 27 Apr 2022 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
President and CEO, Director
Signature
/s/ David H. Mack
Issuer symbol
PMVP
Transactions as of
27 Apr 2022
Net transactions value
+$17,490
Form type
4
Filing time
29 Apr 2022, 21:15:13 UTC
Previous filing
09 Mar 2022
Next filing
15 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Options Exercise $17,490 +33,000 +70% $0.5300* 79,970 27 Apr 2022 Direct
holding PMVP Common Stock 147,915 27 Apr 2022 See footnote F1
holding PMVP Common Stock 80,000 27 Apr 2022 See footnote F2
holding PMVP Common Stock 56,978 27 Apr 2022 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Employee Stock Option (right to buy) Options Exercise $0 -33,000 -7.7% $0.000000 393,366 27 Apr 2022 Common Stock 33,000 $0.5300 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held of record by The Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F2 The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F3 The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F4 The shares subject to the option are fully vested and immediately exercisable.
F5 Due to an administrative error, the Form 4 filed on May 24, 2021 overstated the number of derivative securities beneficially owned following the reported transaction by 6,207 shares and has been updated in this Form 4 to correct the error.